Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis

被引:22
作者
Bail, Kathrin [1 ]
Notz, Quirin [1 ]
Rovituso, Damiano M. [1 ]
Schampel, Andrea [1 ]
Wunsch, Marie [1 ]
Koeniger, Tobias [1 ]
Schropp, Verena [6 ]
Bharti, Richa [2 ]
Scholz, Claus-Juergen [2 ,3 ]
Foerstner, Konrad U. [2 ]
Kleinschnitz, Christoph [4 ,5 ]
Kuerten, Stefanie [1 ,6 ]
机构
[1] Univ Wurzburg, Dept Anat & Cell Biol, Wurzburg, Germany
[2] Univ Hosp Wurzburg, Core Unit Syst Med, Wurzburg, Germany
[3] Univ Bonn, LIMES Inst, Bonn, Germany
[4] Univ Hosp Wurzburg, Dept Neurol, Wurzburg, Germany
[5] Univ Hosp Essen, Dept Neurol, Essen, Germany
[6] Friedrich Alexander Univ Erlangen Nurnberg, Inst Anat & Cell Biol, Erlangen, Germany
来源
JOURNAL OF NEUROINFLAMMATION | 2017年 / 14卷
关键词
B cells; EAE; Fingolimod; FTY720; Multiple sclerosis; TLO; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; CORTICAL PATHOLOGY; LYMPHOCYTE EGRESS; FINGOLIMOD FTY720; INFLAMMATION; INDUCTION; FOLLICLES; IMMUNE; IMMUNOSUPPRESSION;
D O I
10.1186/s12974-017-0924-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: MP4-induced experimental autoimmune encephalomyelitis (EAE) is a mouse model of multiple sclerosis (MS), which enables targeted research on B cells, currently much discussed protagonists in MS pathogenesis. Here, we used this model to study the impact of the S1P1 receptor modulator FTY720 (fingolimod) on the autoreactive B cell and antibody response both in the periphery and the central nervous system (CNS). Methods: MP4-immunized mice were treated orally with FTY720 for 30 days at the peak of disease or 50 days after EAE onset. The subsequent disease course was monitored and the MP4-specific B cell/antibody response was measured by ELISPOT and ELISA. RNA sequencing was performed to determine any effects on B cell-relevant gene expression. S1P1 receptor expression by peripheral T and B cells, B cell subset distribution in the spleen and B cell infiltration into the CNS were studied by flow cytometry. The formation of B cell aggregates and of tertiary lymphoid organs (TLOs) was evaluated by histology and immunohistochemistry. Potential direct effects of FTY720 on B cell aggregation were studied in vitro. Results: FTY720 significantly attenuated clinical EAE when treatment was initiated at the peak of EAE. While there was a significant reduction in the number of T cells in the blood after FTY720 treatment, B cells were only slightly diminished. Yet, there was evidence for the modulation of B cell receptor-mediated signaling upon FTY720 treatment. In addition, we detected a significant increase in the percentage of B220(+) B cells in the spleen both in acute and chronic EAE. Whereas acute treatment completely abrogated B cell aggregate formation in the CNS, the numbers of infiltrating B cells and plasma cells were comparable between vehicle-and FTY720-treated mice. In addition, there was no effect on already developed aggregates in chronic EAE. In vitro B cell aggregation assays suggested the absence of a direct effect of FTY720 on B cell aggregation. However, FTY720 impacted the evolution of B cell aggregates into TLOs. Conclusions: The data suggest differential effects of FTY720 on the B cell compartment in MP4-induced EAE.
引用
收藏
页数:15
相关论文
共 46 条
[1]   CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-κB [J].
Bertin, J ;
Wang, L ;
Guo, Y ;
Jacobson, MD ;
Poyet, JL ;
Srinivasula, SM ;
Merriam, S ;
DiStefano, PS ;
Alnemri, ES .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (15) :11877-11882
[2]   FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function [J].
Brinkmann, V ;
Cyster, JG ;
Hla, T .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (07) :1019-1025
[3]   FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression [J].
Brinkmann, V ;
Chen, S ;
Feng, L ;
Pinschewer, D ;
Nikolova, Z ;
Hof, R .
TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) :530-531
[4]   FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system [J].
Brinkmann, Volker .
BRITISH JOURNAL OF PHARMACOLOGY, 2009, 158 (05) :1173-1182
[5]   Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study [J].
Claes, Nele ;
Dhaeze, Tessa ;
Fraussen, Judith ;
Broux, Bieke ;
Van Wijmeersch, Bart ;
Stinissen, Piet ;
Hupperts, Raymond ;
Hellings, Niels ;
Somers, Veerle .
PLOS ONE, 2014, 9 (10)
[6]   Mechanisms of Fingolimod's Efficacy and Adverse Effects in Multiple Sclerosis [J].
Cohen, Jeffrey A. ;
Chun, Jerold .
ANNALS OF NEUROLOGY, 2011, 69 (05) :759-777
[7]   B cells and multiple sclerosis [J].
Franciotta, Diego ;
Salvetti, Marco ;
Lolli, Francesco ;
Serafini, Barbara ;
Aloisi, Francesca .
LANCET NEUROLOGY, 2008, 7 (09) :852-858
[8]   Amelioration of experimental autoimmune encephalomyelitis in lewis rats by FTY720 treatment [J].
Fujino, M ;
Funeshima, N ;
Kitazawa, Y ;
Kimura, H ;
Amemiya, H ;
Suzuki, S ;
Li, XK .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (01) :70-77
[9]   Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation [J].
Garris, Christopher S. ;
Wu, Linfeng ;
Acharya, Swati ;
Arac, Ahmet ;
Blaho, Victoria A. ;
Huang, Yingxiang ;
Moon, Byoung San ;
Axtell, Robert C. ;
Ho, Peggy P. ;
Steinberg, Gary K. ;
Lewis, David B. ;
Sobel, Raymond A. ;
Han, David K. ;
Steinman, Lawrence ;
Snyder, Michael P. ;
Hla, Timothy ;
Han, May H. .
NATURE IMMUNOLOGY, 2013, 14 (11) :1166-U128
[10]   Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells [J].
Gray, M. ;
Miles, K. ;
Salter, D. ;
Gray, D. ;
Savill, J. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (35) :14080-14085